A retrospective analysis determined that use of G-CSFs, ESAs, and RBC transfusions were reduced in patients who received trilaciclib prior to chemotherapy for ES-SCLC.
Researchers sought to determine the effectiveness of targeted nonelectronic outreach methods in marginalized populations.
A single-center study found anti-COVID-19 protection lowest in patients with MM at 2 weeks after their second BNT162b2 mRNA shot than did patients with myeloproliferative malignancies, and was highest in older patients without cancer.
Researchers sought to determine the effect this regimen on outcomes for patients with early-stage non-small cell lung cancer.
